Insights & news

European Union Task Force Publishes Guidance Tackling Medicine Shortage Issues

  • 08/07/2019
  • Articles

A European Union task force set up to address medicine supply problems published on 4 July 2019 two documents on the subject as follows:

  •  Guidance on detection and notification of shortages of medicinal products for Marketing Authorisation Holders in the Union (EEA) (“Document 1” - attached); and
     
  •  Good practice guidance for communication to the public on medicines’ availability issues (“Document 2” - attached).

The task force was established by the European Medicines Agency (“EMA”) and the Heads of Medicines Agencies (“HMA”), with representatives from the European Commission and national competent authorities, the chairs of the Co-ordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh) and Veterinary (CMDv), the Good Manufacturing Practices/Good Distribution Practices Inspectors Working Group, the Working Group of Communication Professionals (“WGCP”) and the European Surveillance Strategy Working Group (“ESS WG”).

Document 1 offers guidance to the pharmaceutical industry to facilitate the detection and early notification of medicine shortages to competent authorities. The guidance is based on a common EU definition of the term ‘shortage’ which is said to occur when supply does not meet demand at a national level. In that definition, the notion of supply refers to the total volume of stock of the individual medicinal product that is placed on the market by the Marketing Authorisation Holder. Demand relates to the request for a medicinal product by a healthcare professional, veterinarian or patient in response to a clinical need.

On the basis of this definition, Document 1 explains the issues that form the subject of notification; the party responsible for the notification; the time of notification; the bodies that should be notified; and the information which a notification should cover. Document 1 also contains a handy proposed template for shortage notification. The guidance and template will be implemented in a pilot phase which is currently scheduled to start in the last quarter of 2019.

Document 2 is addressed to EU national competent authorities and EMA and lays out principles and examples of good practices for communication on shortages to the public, including patients and healthcare professionals. The guidance is based on a survey carried out by the task force in all EU Member States to collect information on how issues related to shortages and availability of medicines are measured and communicated to the public.

Significantly, in presenting the guidance, EMA described medicine shortages as a “a key public health priority for the EU network”. At the same time, EMA also acknowledged that medicine “[s]hortages and availability problems are complex with no quick solutions”.

Attachments:

Key contacts

Related practice areas

Related insights

Sign up for updates
    • 04/06/2020
    • Articles

    Europe - Four-Country Inclusive Vaccine Alliance In Quest for Covid-19 Vaccine

    In a letter to Parliament and a press release (see, attachments), the Dutch Minister for Public Health, Wellbeing and Sports, Hugo de Jonge, revealed on 3 June 2020 an initiative of Italy, France, Germany and The Netherlands to work together to secure a Covid-19 vaccine for “the European Union and other countries”.   According to the Minister, the “Inclusive Vaccine Alliance” (IVA) is in talks with several pharmaceutical companies regarding promising ventures and in the process hopes to establish a European manufacturing base for the vaccine. The IVA’s ultimate goal is to create a medicine that is “accessible, available and affordable”.   Other countries will be given the opportunity to join the IVA which is also in contact with the European Commission.

    Read more
    • 03/06/2020
    • Articles

    European Commission Publishes Roadmap Towards Pharmaceutical Strategy for Europe

    The European Commission (the Commission) published on 2 June 2020 its roadmap towards a Pharmaceutical Strategy for Europe (PSE) which it plans to publish in the fourth quarter of 2020 (see, attachment). The roadmap defines the steps which the Commission will take prior to adopting the PSE and the data which it will assemble to inform its PSE. While the Commission will consult a range of stakeholders, it has already announced a public consultation which will run until 7 July 2020.

    Read more
    • 02/06/2020
    • Articles

    Italian Competition Authority Approves Scheme for Distribution of Surgical Masks

    On 1 June 2020, the Italian competition authority (“L’Autorità Garante della Concorrenza e del Mercato”) authorised a scheme that would allow disposable surgical masks to be distributed and sold in pharmacies and health product retail outlets (see, attached press release). It did so at the request of the two principal Italian associations of pharmaceutical wholesalers. Under the scheme, the wholesalers and associations of pharmacists and health product retailers acquire the masks in a joint procurement procedure. The masks are then allocated among the wholesalers at a uniform price per unit that was agreed upon with the suppliers. The scheme will last until 30 June 2020. The competition authority approved the scheme because it solves an urgent and wide-ranging health problem and is limited in time. It thus applied for the first time the principles of its guidance of 22 April 2020 regarding cooperation agreements designed to ensure the distribution of scarce essential goods and services, including health products and food. The competition authority’s approach is in line with the views expressed by the European Commission and competition authorities around Europe to address the problems resulting from the Covid-19 pandemic (see e.g., Van Bael & Bellis Life Sciences News Alert of 9 April 2020 and of 26 May 2020). Not coincidentally, the competition authority indicates that it obtained counsel from the European Commission.

    Read more

Subscribe to our updates

Please select the practice areas you are interested in: *